SE450088B - Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer - Google Patents
Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorerInfo
- Publication number
- SE450088B SE450088B SE8101582A SE8101582A SE450088B SE 450088 B SE450088 B SE 450088B SE 8101582 A SE8101582 A SE 8101582A SE 8101582 A SE8101582 A SE 8101582A SE 450088 B SE450088 B SE 450088B
- Authority
- SE
- Sweden
- Prior art keywords
- mice
- granulosum
- preparations
- tumors
- treatment
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 22
- 206010028980 Neoplasm Diseases 0.000 title claims description 21
- 210000004027 cell Anatomy 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title claims description 13
- 210000002421 cell wall Anatomy 0.000 title claims description 11
- 241000894006 Bacteria Species 0.000 title description 5
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 40
- 241001464974 Cutibacterium avidum Species 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 229940055009 propionibacterium avidum Drugs 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 46
- 210000000952 spleen Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 208000006268 Sarcoma 180 Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 241001655324 Propionibacteriales Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 102100036364 Cadherin-2 Human genes 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000000904 thermoluminescence Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3011461A DE3011461C2 (de) | 1980-03-25 | 1980-03-25 | Verwendung von Propionibakterien |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8101582L SE8101582L (sv) | 1982-09-13 |
| SE450088B true SE450088B (sv) | 1987-06-09 |
Family
ID=6098254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8101582A SE450088B (sv) | 1980-03-25 | 1981-03-12 | Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4647456A (nl) |
| JP (1) | JPS57165319A (nl) |
| AT (1) | AT371714B (nl) |
| AU (1) | AU548596B2 (nl) |
| BE (1) | BE888770A (nl) |
| CA (1) | CA1197798A (nl) |
| CH (1) | CH661868A5 (nl) |
| DE (1) | DE3011461C2 (nl) |
| FR (1) | FR2505186A1 (nl) |
| GB (1) | GB2098478B (nl) |
| NL (1) | NL189947C (nl) |
| NO (1) | NO162079C (nl) |
| SE (1) | SE450088B (nl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678773A (en) * | 1983-08-26 | 1987-07-07 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent |
| DE3817762A1 (de) * | 1988-05-26 | 1989-11-30 | Sanum Kehlbeck Gmbh & Co Kg | Immunstimulierendes mittel aus propionibakterien sowie verfahren zur herstellung desselben |
| IL101410A0 (en) * | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
| DE19630230A1 (de) * | 1996-07-26 | 1998-01-29 | Bayer Ag | Herstellung immunstimulierender Mittel auf Basis von Propionibakterien |
| FR2764802A1 (fr) * | 1996-12-24 | 1998-12-24 | Standa Lab Sa | Composition adsorbable renfermant des bacteries propioniques susceptible de degager du monoxyde d'azote dans le tube digestif humain ou animal |
| ATE227996T1 (de) | 1997-08-05 | 2002-12-15 | Bioniche Life Sciences Inc | Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod |
| CN1187043C (zh) * | 1999-10-19 | 2005-02-02 | 明治乳业株式会社 | 用于防止和改善代谢性骨病的食品材料和包含这些材料的用于代谢性骨病的预防药/治疗药 |
| ES2340807T3 (es) * | 1999-12-13 | 2010-06-09 | Bioniche Life Sciences Inc. | Oligonucleotidos sinteticos utiles terapeuticamente. |
| EP1250152B1 (en) * | 1999-12-28 | 2013-05-15 | Bioniche Urology IP Inc. | Synergistic composition containing hyaluronic acid in the treatment of cancer |
| GB2623078A (en) * | 2022-10-03 | 2024-04-10 | Univ Brunel | Prevention and/or treatment of wound infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2269961B1 (nl) * | 1974-05-06 | 1978-03-24 | Anvar | |
| FR2269962B1 (nl) * | 1974-05-06 | 1978-02-03 | Anvar | |
| JPS5215894A (en) * | 1975-07-29 | 1977-02-05 | Yuichi Yamamura | Process for preparing a substance possessing biological actions |
| JPS5946206B2 (ja) * | 1975-10-08 | 1984-11-10 | （株） 目黒研究所 | 免疫学的活性を有する非病原性好気性コリネバクテリウム培養物の製造法 |
| JPS52108091A (en) * | 1976-03-03 | 1977-09-10 | Kowa Co | Production of antiitumor substance |
| JPS5411233A (en) * | 1977-06-28 | 1979-01-27 | Asahi Chem Ind Co Ltd | Anitidote |
| JPS5513204A (en) * | 1978-06-28 | 1980-01-30 | Mitsui Toatsu Chem Inc | Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation |
| JPS55114290A (en) * | 1979-02-27 | 1980-09-03 | Mitsui Toatsu Chem Inc | Substance with antitumorigenic activity, its production and medical preparation |
-
1980
- 1980-03-25 DE DE3011461A patent/DE3011461C2/de not_active Expired
-
1981
- 1981-03-10 NO NO810815A patent/NO162079C/no not_active IP Right Cessation
- 1981-03-12 SE SE8101582A patent/SE450088B/sv not_active IP Right Cessation
- 1981-03-13 AT AT0118981A patent/AT371714B/de not_active IP Right Cessation
- 1981-03-24 NL NLAANVRAGE8101452,A patent/NL189947C/nl not_active IP Right Cessation
- 1981-03-27 CH CH2100/81A patent/CH661868A5/de not_active IP Right Cessation
- 1981-04-02 JP JP56050014A patent/JPS57165319A/ja active Granted
- 1981-05-06 CA CA000376972A patent/CA1197798A/en not_active Expired
- 1981-05-07 AU AU70242/81A patent/AU548596B2/en not_active Ceased
- 1981-05-08 FR FR8109265A patent/FR2505186A1/fr active Granted
- 1981-05-12 BE BE0/204763A patent/BE888770A/fr not_active IP Right Cessation
- 1981-05-15 GB GB8114915A patent/GB2098478B/en not_active Expired
-
1985
- 1985-01-03 US US06/688,278 patent/US4647456A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NO162079C (no) | 1989-11-01 |
| AT371714B (de) | 1983-07-25 |
| FR2505186A1 (fr) | 1982-11-12 |
| JPS57165319A (en) | 1982-10-12 |
| CH661868A5 (de) | 1987-08-31 |
| JPH0355448B2 (nl) | 1991-08-23 |
| BE888770A (fr) | 1981-11-12 |
| DE3011461A1 (de) | 1981-10-01 |
| NL189947C (nl) | 1993-09-16 |
| AU7024281A (en) | 1982-11-11 |
| NL8101452A (nl) | 1982-10-18 |
| AU548596B2 (en) | 1985-12-19 |
| CA1197798A (en) | 1985-12-10 |
| FR2505186B1 (nl) | 1984-10-12 |
| DE3011461C2 (de) | 1986-10-30 |
| NO162079B (no) | 1989-07-24 |
| NL189947B (nl) | 1993-04-16 |
| US4647456A (en) | 1987-03-03 |
| SE8101582L (sv) | 1982-09-13 |
| NO810815L (no) | 1982-09-13 |
| ATA118981A (de) | 1982-10-15 |
| GB2098478A (en) | 1982-11-24 |
| GB2098478B (en) | 1985-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sidransky et al. | The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis | |
| Bulmer et al. | Phagocytosis of Cryptococcus neoformans by alveolar macrophages | |
| Baumgartner et al. | Experimentally induced infection by oral anaerobic microorganisms in a mouse model | |
| EP2286832B1 (en) | Bacterial compositions for the treatment of cancer | |
| Gordon et al. | Studies on susceptibility to infection following ionizing radiation: IV. The pathogenesis of the endogenous bacteremias in mice | |
| Davies et al. | Human protothecosis: supplementary studies | |
| Belsheim et al. | Tetracyclines and host defense mechanisms: interference with leukocyte chemotaxis | |
| SE450088B (sv) | Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer | |
| Chu et al. | Cutaneous cryptococcosis | |
| US3928565A (en) | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties | |
| Bluhm et al. | Antibiotic prophylaxis in pacemaker surgery: a prospective double blind trial with systemic administration of antibiotic versus placebo at implantation of cardiac pacemakers | |
| Olson et al. | Measles pneumonia: bacterial suprainfection as a complicating factor | |
| Bullock et al. | On a new factor in the mechanism of bacterial infection | |
| Balner et al. | Reduction of X-ray lethality in mice by agents affecting the reticuloendothelial system | |
| Warring Jr et al. | Nonculturable acid-fast forms in the sputum of patients with tuberculosis and chronic pulmonary disease | |
| Pierangeli et al. | Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa | |
| Campbell et al. | An apparent growth stimulant for Candida albicans released from tetracycline-treated bacterial flora | |
| Fitzgeorge et al. | The chemical basis of the virulence of Brucella abortus. VII. The production in vitro of organisms with an enhanced capacity to survive intracellularly in bovine phagocytes. | |
| Perkins et al. | Susceptibility to infection as a function of postirradiation time following oral challenge | |
| Patton et al. | Histoplasmosis in purebred mice: influence of genetic susceptibility and immune depression on treatment | |
| KD | The prognosis and treatment of sprue in India. | |
| Ransmeier | The effect of aureomycin against Bacterium tularense | |
| Okuda et al. | Intraleukocytic bactericidal activity in patients receiving corticosteroid and radiation therapy, and in patients with diabetes mellitus | |
| Walker | On the lack of evidence of transmission by human beings of tuberculosis due to the bovine type of bacillus | |
| BAUME et al. | The source of a gastric secretory inhibitor from human saliva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8101582-8 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8101582-8 Format of ref document f/p: F |